Pediatric Gastroenterology Fellowship Program, Nationwide Children's Hospital, Columbus, OH, USA.
J Pediatr Gastroenterol Nutr. 2012 Dec;55(6):701-6. doi: 10.1097/MPG.0b013e318266241b.
To examine sex differences in medical therapy and clinical outcomes in pediatric patients with inflammatory bowel disease (IBD).
We performed a cross-sectional analysis of children with Crohn disease (CD) and ulcerative colitis (UC) using data from the ImproveCareNow Network collected between May 2007 and May 2010. Clinical remission, disease severity, body mass index (BMI) z scores, normal height velocity, and medication use were analyzed by sex and age.
One thousand four hundred nine patients were included (993 had CD and 416 had UC). No significant sex differences were found in disease severity, BMI, height velocity, or use of medications. Further analysis of combination therapy with infliximab + 6-mercaptopurine/azathioprine and infliximab + methotrexate also did not reveal any differences. No sex differences were found after mediation use was stratified by age (those younger than 13 years and those 13 years old or older).
In this sample of CD and UC pediatric patients, no significant sex differences were found in disease severity, BMI, height velocity, or medication use. Our data do not support the use of sex as a major factor in patient risk stratification for children with IBD. In addition, despite concerns for sex-specific complications of some medications, our analysis did not suggest any sex differences in medication use.
探讨炎症性肠病（IBD）儿科患者中医学治疗与临床结局的性别差异。
我们对 2007 年 5 月至 2010 年 5 月期间 ImproveCareNow 网络收集的数据进行了一项横断面分析，纳入克罗恩病（CD）和溃疡性结肠炎（UC）患儿。根据性别和年龄分析临床缓解、疾病严重程度、体重指数（BMI）z 评分、正常身高增长速度和药物使用情况。
共纳入 1409 例患者（993 例 CD，416 例 UC）。疾病严重程度、BMI、身高增长速度或药物使用方面无明显性别差异。进一步分析英夫利昔单抗联合 6-巯基嘌呤/硫唑嘌呤和英夫利昔单抗联合甲氨蝶呤的联合治疗也未发现差异。经年龄分层（<13 岁和≥13 岁）后，使用调节药物也未发现性别差异。
在本 CD 和 UC 儿科患者样本中，疾病严重程度、BMI、身高增长速度或药物使用方面无明显性别差异。我们的数据不支持将性别作为 IBD 患儿患者分层的主要因素。此外，尽管某些药物存在特定性别并发症的担忧，但我们的分析并未提示药物使用存在任何性别差异。
